MiMedx Group, Inc. (MDXG)

MiMedx Group's stock has been influenced by strong earnings reports, including record Q2 and Q3 2025 revenues. The company entered an exclusive distribution agreement with Regen Lab USA for RegenKit®-Wound Gel. MiMedx commented on the CY 2026 Medicare Physician Fee Schedule Final Rule, proactively managing reimbursement policy risks. The share price declined by 27.05% between January 2025 and January 2026, but analysts maintain a "Moderate Buy" rating with a potential upside of 87.07%.

MiMedx Group's Free Cash Flow (FCF) margin varies seasonally, although specific patterns of demand fluctuation for its products and services are not detailed in the available information.

MiMedx Group, Inc. is a biopharmaceutical company specializing in regenerative biologics derived from human placental allografts. The company develops, manufactures, and markets regenerative biomaterial products and bioimplants derived from human placental tissues, utilizing a proprietary PURION process. MiMedx's products modulate inflammation, reduce scar tissue formation, and enhance healing in various healthcare sectors, including wound care, surgical recovery, orthopedics, and ophthalmology. Major products include Advanced Wound Solutions (EPIFIX, EPICORD, EPIEFFECT), Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN), and other technologies like CollaFix and OrthoFlo.

MiMedx Group's operations are primarily located in Marietta, Georgia, which houses its corporate headquarters, development, sales, manufacturing, and distribution functions. Additionally, it has a research and early-stage product development facility in Tampa, Florida. MiMedx aims to expand internationally, starting with EPIFIX® in Japan, and distributes its products through various channels, including direct sales, independent agents, and third-party licenses.

MiMedx Group's brand reputation has been positively influenced by scientific advancements and clinical trial updates. The company announced a publication in the Journal of Inflammation focusing on the immunomodulatory effects of its Purion® Processed Human Amniotic Membrane Allografts In Vitro and provided an update on its EPIEFFECT® Randomized Controlled Trial. No specific negative events impacting the company's reputation were found within the past year.

MiMedx Group has a mixed ownership structure, with institutional investors holding between 46.84% and 70.56% of the stock, and insiders holding between 2.13% and 81.39%. Major institutional owners include Essex Woodlands Management, Inc., BlackRock, Inc., and Vanguard Group Inc. Significant individual and insider owners include Falcon Fund 2 Holding Company LP and Martin P. Sutter.